GlassScriptPhysician profile
Joshua Z Steiner
NPI 1427046887
$13,143.48
in general payments reported to CMS, 2019-2025
61 companies · $1,238 in 2025
The $1,238 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,918 · 2020: $2,669 · 2021: $2,479 · 2022: $2,160 · 2023: $1,678 · 2024: $1,001 · 2025: $1,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,818 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,818.04 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,102.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $899.81 | 2019-2025 | |
| Glaxosmithkline, LLC. | $874.72 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $843.19 | 2019-2025 | Qulipta, Ubrelvy, Synthroid |
| Lilly USA, LLC | $733.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $589.65 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $453.25 | 2019-2025 | Farxiga, Evusheld, Airsupra |
| Astellas Pharma US INC | $423.86 | 2019-2025 | Veozah, Izervay, Myrbetriq |
| Abbott Laboratories | $410.08 | 2020-2024 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.86 | 2019-2025 | Jardiance, Synjardy, Glyxambi |
| Takeda Pharmaceuticals U.S.A., INC. | $364.04 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $325.08 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $316.35 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $315.53 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $295.02 | 2019-2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Steiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.